Mathematically modelling and controlling prostate cancer under intermittent hormone therapy.
In this review, we summarize our recently developed mathematical models that predict the effects of intermittent androgen suppression therapy on prostate cancer (PCa). Although hormone therapy for PCa shows remarkable results at the beginning of treatment, cancer cells frequently acquire the ability to grow without androgens during long-term therapy, resulting in an eventual relapse. To circumvent hormone resistance, intermittent androgen suppression was investigated as an alternative treatment option. However, at the present time, it is not possible to select an optimal schedule of on- and off-treatment cycles for any given patient. In addition, clinical trials have revealed that intermittent androgen suppression is effective for some patients but not for others. To resolve these two problems, we have developed mathematical models for PCa under intermittent androgen suppression. The mathematical models not only explain the mechanisms of intermittent androgen suppression but also provide an optimal treatment schedule for the on- and off-treatment periods.
Institute of Industrial Science, University of Tokyo, Tokyo 153-8505, Japan.
Yoshito
Y
Hirata
Gouhei
G
Tanaka
Nicholas
N
Bruchovsky
Kazuyuki
K
Aihara
D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use*; D049109:Cell Proliferation / Q000187:drug effects; D004334:Drug Administration Schedule; D006801:Humans; D015994:Incidence; D008297:Male; D008962:Models, Theoretical; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000726:Androgen Antagonists